Business & Economy · Boston ·
Boston biotech Rezera delays $200 million IPO
Rezera postponed its $200 million initial public offering, citing market conditions, according to The Boston Globe.
1 report
Headline and summary written by the Acta Diurna desk using only what the outlets above reported. Read their reporting for the full story. How we stay neutral.
Boston news today · More Business & Economy · Boston prediction markets